Cargando…
A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia
Long-term survival still eludes most patients with leukemia and non-Hodgkin’s lymphoma. No approved therapies target the hallmark of the B cell, its mIgM, also known as the B-cell receptor (BCR). Aptamers are small oligonucleotides that can specifically bind to a wide range of target molecules and o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064813/ https://www.ncbi.nlm.nih.gov/pubmed/21030439 http://dx.doi.org/10.1093/nar/gkq996 |
_version_ | 1782200925823172608 |
---|---|
author | Mallikaratchy, Prabodhika R. Ruggiero, Alessandro Gardner, Jeffrey R. Kuryavyi, Vitaly Maguire, William F. Heaney, Mark L. McDevitt, Michael R. Patel, Dinshaw J. Scheinberg, David A. |
author_facet | Mallikaratchy, Prabodhika R. Ruggiero, Alessandro Gardner, Jeffrey R. Kuryavyi, Vitaly Maguire, William F. Heaney, Mark L. McDevitt, Michael R. Patel, Dinshaw J. Scheinberg, David A. |
author_sort | Mallikaratchy, Prabodhika R. |
collection | PubMed |
description | Long-term survival still eludes most patients with leukemia and non-Hodgkin’s lymphoma. No approved therapies target the hallmark of the B cell, its mIgM, also known as the B-cell receptor (BCR). Aptamers are small oligonucleotides that can specifically bind to a wide range of target molecules and offer some advantages over antibodies as therapeutic agents. Here, we report the rational engineering of aptamer TD05 into multimeric forms reactive with the BCR that may be useful in biomedical applications. Systematic truncation of TD05 coupled with modification with locked nucleic acids (LNA) increased conformational stability and nuclease resistance. Trimeric and tetrameric versions with optimized polyethyleneglycol (PEG) linker lengths exhibited high avidity at physiological temperatures both in vitro and in vivo. Competition and protease studies showed that the multimeric, optimized aptamer bound to membrane-associated human mIgM, but not with soluble IgM in plasma, allowing the possibility of targeting leukemias and lymphomas in vivo. The B-cell specificity of the multivalent aptamer was confirmed on lymphoma cell lines and fresh clinical leukemia samples. The chemically engineered aptamers, with significantly improved kinetic and biochemical features, unique specificity and desirable pharmacological properties, may be useful in biomedical applications. |
format | Text |
id | pubmed-3064813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-30648132011-03-28 A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia Mallikaratchy, Prabodhika R. Ruggiero, Alessandro Gardner, Jeffrey R. Kuryavyi, Vitaly Maguire, William F. Heaney, Mark L. McDevitt, Michael R. Patel, Dinshaw J. Scheinberg, David A. Nucleic Acids Res Synthetic Biology and Chemistry Long-term survival still eludes most patients with leukemia and non-Hodgkin’s lymphoma. No approved therapies target the hallmark of the B cell, its mIgM, also known as the B-cell receptor (BCR). Aptamers are small oligonucleotides that can specifically bind to a wide range of target molecules and offer some advantages over antibodies as therapeutic agents. Here, we report the rational engineering of aptamer TD05 into multimeric forms reactive with the BCR that may be useful in biomedical applications. Systematic truncation of TD05 coupled with modification with locked nucleic acids (LNA) increased conformational stability and nuclease resistance. Trimeric and tetrameric versions with optimized polyethyleneglycol (PEG) linker lengths exhibited high avidity at physiological temperatures both in vitro and in vivo. Competition and protease studies showed that the multimeric, optimized aptamer bound to membrane-associated human mIgM, but not with soluble IgM in plasma, allowing the possibility of targeting leukemias and lymphomas in vivo. The B-cell specificity of the multivalent aptamer was confirmed on lymphoma cell lines and fresh clinical leukemia samples. The chemically engineered aptamers, with significantly improved kinetic and biochemical features, unique specificity and desirable pharmacological properties, may be useful in biomedical applications. Oxford University Press 2011-03 2010-10-28 /pmc/articles/PMC3064813/ /pubmed/21030439 http://dx.doi.org/10.1093/nar/gkq996 Text en © The Author(s) 2010. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/2.5 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Synthetic Biology and Chemistry Mallikaratchy, Prabodhika R. Ruggiero, Alessandro Gardner, Jeffrey R. Kuryavyi, Vitaly Maguire, William F. Heaney, Mark L. McDevitt, Michael R. Patel, Dinshaw J. Scheinberg, David A. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia |
title | A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia |
title_full | A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia |
title_fullStr | A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia |
title_full_unstemmed | A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia |
title_short | A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia |
title_sort | multivalent dna aptamer specific for the b-cell receptor on human lymphoma and leukemia |
topic | Synthetic Biology and Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064813/ https://www.ncbi.nlm.nih.gov/pubmed/21030439 http://dx.doi.org/10.1093/nar/gkq996 |
work_keys_str_mv | AT mallikaratchyprabodhikar amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT ruggieroalessandro amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT gardnerjeffreyr amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT kuryavyivitaly amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT maguirewilliamf amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT heaneymarkl amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT mcdevittmichaelr amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT pateldinshawj amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT scheinbergdavida amultivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT mallikaratchyprabodhikar multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT ruggieroalessandro multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT gardnerjeffreyr multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT kuryavyivitaly multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT maguirewilliamf multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT heaneymarkl multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT mcdevittmichaelr multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT pateldinshawj multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia AT scheinbergdavida multivalentdnaaptamerspecificforthebcellreceptoronhumanlymphomaandleukemia |